John Ruesch
Corporate Officer/Principal at ASTRIA THERAPEUTICS, INC.
Profile
John Ruesch is currently the Senior Vice President-Pharmaceutical Sciences at Astria Therapeutics, Inc. Prior to this, he worked as the Vice President-Pharmaceutical Development at Surface Oncology, Inc. Mr. Ruesch completed his undergraduate degree at Valparaiso University and earned an MBA from Kellogg School of Management.
John Ruesch active positions
| Companies | Position | Start |
|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Corporate Officer/Principal | 2023-07-16 |
Former positions of John Ruesch
| Companies | Position | End |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | - |
Training of John Ruesch
| Valparaiso University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- John Ruesch
